StockSelector.com
  Research, Select, & Monitor Saturday, June 23, 2018 3:37:48 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Anika Therapeutics Inc.$30.97$1.244.17%

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Anika Therapeutics Inc. has an overall rank of 1840 out of 7142 stocks based on 13 positive rankings and 8 negative rankings.

Positive Rankings
Debt-to-Equity
Anika Therapeutics Inc. rank is 115
Target Prices
The average analysts' target price is $39.00 for Anika Therapeutics Inc. using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Anika Therapeutics Inc. is ranked 224.
Low Put/Call
Anika Therapeutics Inc. has a low Put/Call ratio of 0.12 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Anika Therapeutics Inc. is ranked 317.
Low vPut/Call
Anika Therapeutics Inc. has a low Put/Call ratio of 0.13 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Anika Therapeutics Inc. is ranked 334.
Highest ROA
Anika Therapeutics Inc. rank is 458
Historic EPS Growth
Anika Therapeutics Inc. rank is 564
Highest Cash Growth
Anika Therapeutics Inc. rank is 564
Highest Net Margin
Anika Therapeutics Inc. rank is 653
Oversold Stochastics
Anika Therapeutics Inc. rank is 809
Highest ROE
Anika Therapeutics Inc. rank is 1373
Historic Revenue Growth
Anika Therapeutics Inc. rank is 1376
Price-to-Book
Anika Therapeutics Inc. rank is 1954
Estimated Revenue Growth
Anika Therapeutics Inc. rank is 2058
Negative Rankings
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Anika Therapeutics Inc. is ranked 19.
Negative EPS Growth
Anika Therapeutics Inc. rank is 35
10 Day Loss
Anika Therapeutics Inc. rank is 91
Negative Guidance
Within the past 90 days Anika Therapeutics Inc. has provided guidance belwo the consensus estimates. Statistics show companies that provide negative guidance underperform the market in the short-term.
Down Estimate Revision
During the past month, the consensus earnings estimate for the current year and next year have decreased by a combined (3.20%). Among companies that have had their estimates lowerec within the past month, Anika Therapeutics Inc. is ranked 196.
90 Day Loss
Anika Therapeutics Inc. rank is 227
Down EPS Surprise
Anika Therapeutics Inc. missed the consensus earnings estimate when it last reported quarterly earnings.
Price-to-Sales
Anika Therapeutics Inc. rank is 1516







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.